Page 6 of 7: studies 101 to 120 of 121, newest first. Back to the ketamine overview
January 31, 2019
In this meta-analysis of 10 randomized trials, ketamine was associated with rapid reduction of suicidal ideation, sometimes even without similar reductions in depression. The effect persisted for 7 days.
Psychiatry Research Neuroimaging January 30, 2019 Allison C. Nugent, Kathleen E. Wills, Jessica R. Gilbert et al.
Preclinical and clinical evidence has demonstrated that ketamine has rapid antidepressant effects. Studies using pre-treatment with an AMPA inhibitor suggest that enhancing AMPA throughput is crucial to ketamine's effects, including increases in both basal and evoked gamma power. This study sought to replicate previous findings of increased gamma response to a somatosensory stimulus at 230 min...
January 23, 2019 Samuel T. Wilkinson
Define the therapeutic role of ketamine in depression and suicidal ideation. Outline the safety concerns related to the use of ketamine in psychiatric practice.
Journal of Psychopharmacology January 21, 2019 Rebecca McMillan, Anna Forsyth, Doug Campbell et al. 23 citations
BACKGROUND: Pharmacological magnetic resonance imaging has been used to investigate the neural effects of subanaesthetic ketamine in healthy volunteers. However, the effect of ketamine has been modelled with a single time course and without consideration of physiological noise. AIMS: This study aimed to investigate ketamine-induced alterations in resting neural activity using conventional...
Frontiers in Psychiatry January 17, 2019 Santiago Castro-Zaballa, Matías Cavelli, Joaquín González et al.
Cognitive processes are carried out during wakefulness by means of extensive interactions between cortical and subcortical areas. In psychiatric conditions, such as psychosis, these processes are altered. Interestingly, REM sleep where most dreams occurs, shares electrophysiological, pharmacological, and neurochemical features with psychosis. Because of this fact, REM sleep is considered a...
IBRO Reports January 16, 2019 Michael Zhang, Kennett D. Radford, Mercedes Y. Driscoll et al. 34 citations
Ketamine, a multimodal dissociative anesthetic, is a powerful analgesic administered following trauma due to its hemodynamic and respiratory stability. However, ketamine can cause hallucination and dissociation which may adversely impact traumatic memory after an injury. The effects of ketamine on proteins implicated in neural plasticity are unclear due to different doses, routes, and timing of...
Neuroimage January 11, 2019 Michele A. Colombo, Martino Napolitani, Melanie Boly et al. 359 citations
Despite the absence of responsiveness during anesthesia, conscious experience may persist. However, reliable, easily acquirable and interpretable neurophysiological markers of the presence of consciousness in unresponsive states are still missing. A promising marker is based on the decay-rate of the power spectral density (PSD) of the resting EEG. We acquired resting electroencephalogram (EEG)...
Progress in Neuro-Psychopharmacology and Biological Psychiatry January 10, 2019 Nerea Llamosas, Laura Perez-Caballero, Esther Berrocoso et al.
Accumulating evidence indicates that the antidepressant effects of ketamine are, in part, mediated by an increase in the AMPA receptor-mediated neurotransmission in depression related areas, such as the prefrontal cortex (PFC). Therefore, activity in PFC-projecting areas related to major depression, such as the dorsal raphe nucleus (DR), may also be modulated by ketamine. We used whole-cell...
American Journal of Psychiatry January 4, 2019 Satoshi Deyama, Eunyoung Bang, Eric S. Wohleb et al. 100 citations
OBJECTIVE: -methyl-d-aspartate receptor antagonist ketamine produces rapid and sustained antidepressant actions even in patients with treatment-resistant depression. Vascular endothelial growth factor (VEGF) has been implicated in the effects of conventional monoamine-based antidepressants, but the role of VEGF in the rapid antidepressant actions of ketamine remains unclear. The authors...
Neuropsychopharmacology January 2019 Mark Jeremy Hunt, Natalie E Adams, Władysław Średniawa et al.
High-frequency neuronal population oscillations (HFO, 130-180 Hz) are robustly potentiated by subanesthetic doses of ketamine. This frequency band has been recorded in functionally and neuroanatomically diverse cortical and subcortical regions, notably ventral striatal areas. However, the locus of generation remains largely unknown. There is compelling evidence that olfactory regions can drive...
African journal of emergency medicine : Revue africaine de la medecine d'urgence 2019 Sarah Villegas, Sebastian Suarez, Joseph Owuor et al.
Five of the 7.2 billion people on earth have limited access to emergency and essential surgical procedures. The lack of safe, affordable and timely anaesthesia services are primary barriers to universal surgical coverage. The objective of this study was to assess intraoperative awareness when the 'Every Second Matters for Emergency and Essential Surgery - Ketamine' (ESM-Ketamine) package was...
Chronic Stress 2019 Ginetta Collo, Laura Cavalleri, Emilio Merlo Pich
The mechanisms underlying the antidepressant effects of ketamine in treatment-resistant depression are only partially understood. Reactivation of neural plasticity in prefrontal cortex has been considered critical in mediating the effects of standard antidepressants, but in treatment-resistant depression patients with severe anhedonia, other components of the affected brain circuits, for...
Pharmacology, Biochemistry, and Behavior 2019 Nian-nian Huang, Dongyu Hua, Gaofeng Zhan et al.
ABSTRACT Ketamine, an N‐methyl‐d‐aspartic acid receptor (NMDAR) antagonist, elicits rapid‐acting and sustained antidepressant effects in treatment‐resistant depressed patients. Accumulating evidence suggests that gut microbiota via the gut‐brain axis play a role in the pathogenesis of depression, thereby contributing to the antidepressant actions of certain compounds. Here we investigated the...
Chronic Stress 2019 Katherine N Wright, Devin P Hagarty, C. Strong et al.
Background Ketamine has rapid antidepressant effects and shows great promise as a novel treatment for depression, but its limitations including its abuse potential are poorly understood. Given that the prevalence of depression is twice as high in women as in men and that depression and substance use disorders are highly comorbid, we hypothesized that a sex-specific responsivity to behavioral...
Handbook of experimental pharmacology 2019 Nuri B Farber
Fifteen to thirty percent of patients with major depressive disorder do not respond to antidepressants that target the monoaminergic systems. NMDA antagonists are currently being actively investigated as a treatment for these patients. Ketamine is the most widely studied of the compounds. A brief infusion of a low dose of this agent produces rapid improvement in depressive symptoms that lasts...
Archives of Psychiatry and Behavioral Sciences 2019 Michael Hart, Zack Z. Cernovsky 1 citation
present study extends the application of ketamine to patients with history of not only chronic
Journal of Affective Disorders 2019 Dawn F. Ionescu, Kate H Bentley, M. Eikermann et al. 179 citations
BACKGROUND Several studies indicate that ketamine has rapid antidepressant effects in patients with treatment-resistant depression (TRD). The extent to which repeated doses of ketamine (versus placebo) reduce depression in the short and long term among outpatients with TRD and chronic, current suicidal ideation remains unknown. METHODS Twenty-six medicated outpatients with severe major...
Depressive Disorders: Mechanisms, Measurement and Management 2019 Min Cai, Huaning Wang, Xia Zhang 4 citations
Numerous antidepressants are available for the treatment of the major depressive disorder (MDD). Unfortunately, the disadvantages of these antidepressive medications, including inadequate treatment response, the therapeutic lag between drug administration and the onset of symptoms alleviation, and the safety consideration limit their clinical use and accelerate the exploration of advanced...
Advances in pharmacology (San Diego, Calif.) 2019 Jeffrey M. Witkin, Anna E Martin, Lalit K Golani et al. 71 citations
Conventional antidepressants (biogenic amine mechanisms) are not fully efficacious (e.g., symptoms remain after treatment, not all patients respond), produce effects only after weeks of daily dosing, and do not impact all disease symptoms. In contrast, a new class of antidepressants has been emerging since 2006 that has demonstrated rapid onset, large effect size, activity after only a single...
Indian Journal of Psychiatry 2019 Suprio Mandal, VinodKumar Sinha, Nishant Goyal 92 citations
BACKGROUND: Severe depressive disorder is among most debilitating condition. Conventional pharmacotherapy usually takes several weeks (usually 4-12 weeks) to improve symptoms. Ketamine is an N-methyl-D aspartate receptor antagonist having rapid action on depressive symptoms. OBJECTIVES: The effect of subanesthetic dose of ketamine was assessed on depressive and anxiety symptoms. Illness...